Mini Review Open Access
Volume 3 | Issue 5 | DOI: https://doi.org/10.33696/immunology.3.115

Glycogen Synthase Kinase-3 (GSK-3) Regulation of Inhibitory Coreceptor Expression in T-cell Immunity

  • 1Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
  • 2Division of Immunology-Oncology, Centre de Recherche-Hospital Maisonneuve Rosemont, Montreal, Quebec, Canada H1T 2M4
+ Affiliations - Affiliations

Corresponding Author

Christopher E. Rudd, christopher.e.rudd@umontreal.ca

Received Date: August 17, 2021

Accepted Date: October 13, 2021


The serine/threonine kinase, glycogen synthase kinase 3 (GSK-3) has been implicated in immune cell activation and function. Our recent studies have shown that the abrogation of GSK-3 activity down-regulates the expression of key inhibitory receptors PD-1 and LAG-3. It also regulates the expression of the transcription factor NFAT which, in turn, is responsible for inhibiting PD-1/ LAG-3 transcription as well as activating the expression of cytolytic effector proteins such as perforin and granzyme B. The role of components of the Wnt signaling pathway in these events remains to be fully uncovered. This mini-review discusses the recent discoveries that have elucidated the role of the GSK-3 signaling pathway in cancer immunotherapy.

Author Information X